Welcome : Guest

SciClone Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about SciClone Pharmaceuticals, Inc., which is principally involved in Pharmaceuticals Business. Illustrated with 70 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-42382
Price: $3500
Company Type: Public
Pages: 72
Date: November 2016
Market Data Tables: 70

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: SciClone Pharmaceuticals, Inc.’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for China, and Rest of the World......3
Cancer Drugs......4
Table 2: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......4
Table 3: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......5
Cancer Market......6
Table 4: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......6
Table 5: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......7
Table 6: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......8
Table 7: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......9
Table 8: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......10
Table 9: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......11
Table 10: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......12
Table 11: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......13
Cancer Patients......14
Table 12: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......14
Table 13: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......15
Table 14: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......16
Table 15: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......17
Table 16: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......18
Table 17: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......19
Table 18: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......20
Table 19: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......21
Table 20: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......22
Table 21: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......23
Table 22: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......24
Table 23: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......25
Table 24: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......26
Table 25: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......27
Table 26: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......28
Table 27: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......29
Table 28: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......30
Table 29: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......31
Table 30: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......32
Table 31: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......33
Table 32: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......34
Cervical Cancer......35
Table 33: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......35
Table 34: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......36
Hematological Cancer......37
Table 35: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......37
Skin Cancer......38
Table 36: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......38
Cancer-Associated Mucositis......39
Table 37: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......39
Chronic Myelogenous Leukemia (CML)......40
Table 38: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......40
Multiple Myeloma......41
Table 39: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......41
Table 40: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......42
Anti-Cancer Drugs......43
Table 41: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......43
Table 42: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......44
Hepatitis B......45
Table 43: No. of Hepatitis B Patients by Region in Europe (2015) - Percentage Market Share Breakdown by Volume for Eastern Europe, and Western Europe......45
Table 44: No. of Hepatitis B Patients by Country in Eastern Europe (2015) - Percentage Market Share Breakdown by Volume for Hungary, Poland, and Romania......46
Table 45: No. of Hepatitis B Patients by Country in West Europe (2015) - Percentage Market Share Breakdown by Volume for France, Germany, Italy, Netherlands, Spain, United Kingdom, and Others......47
Hepatitis C......48
Table 46: Hepatitis C Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno Modulator, Polymerase Inhibitor, Protease Inhibitors, and Others (Includes Ribavirin)......48
Table 47: Hepatitis C Market by Genotype Worldwide (2015) - Percentage Share Breakdown by Value for Genotype 1, Genotype 2 and Others......49
Table 48: Hepatitis C Virus Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno-Modulator, Polymerase Inhibitor, Protease Inhibitors, Ribavirin, and Others......50
Table 49: Hepatitis C Virus Market by Patient Conditions in Europe (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......51
Table 50: No. of Hepatitis C Virus (HCV) Patients by Category in European Union (EU) (2015) - Percentage Market Share Breakdown for GT1, and Non-GT1......52
Table 51: Hepatitis C Virus Market by Patient Conditions in the US (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......53
Table 52: Health Insurance for Hepatitis C Virus (HCV) by Type in the US (2015) - Percentage Market Share Breakdown by Value for Commercial, Dual (Medicare and Medicaid), Medicaid, Medicare (Non- Dual), Prison, Uninsured, and Veteran Affairs......54
Table 53: No. of Hepatitis C Virus (HCV) Patients by Category in the US (2015) - Percentage Market Share Breakdown for GT1 HCV, GT2/3 HCV, and Others......55
Infectious Disease Drugs......56
Table 54: Infectious Disease Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Molecular Diagnostics Infectious Diseases, and Others......56
Table 55: Infectious Disease Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antifungals, Antivirals, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......57
Cancer Drugs......58
Table 56: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......58
Table 57: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......59
Table 58: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......60
Breast Cancer Drugs......61
Table 59: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......61
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......62
Table 60: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......62
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......63
Table 61: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......63
Table 62: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......64
Anti-Infectives......65
Table 63: Market Shares of Leading Anti-Infective Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Bayer AG, Merck & Co., Inc., Vétoquinol S.A., Virbac S.A., Zoetis, Inc. and Others......65
HBV/HCV Therapeutics......66
Table 64: Market Shares of Leading HBV/HCV Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., and Others......66
Table 65: Market Shares of Leading Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Co (BMY), GlaxoSmithKline Plc (GSK), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Vertex Pharmaceuticals, Inc. (VRTX), and Others......67
Hepatitis B Drugs......68
Table 66: Market Shares of Leading Hepatitis B Drug Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bemis Company, Inc.(Baraclude), F. Hoffmann-La Roche AG (Pegasys), GlaxoSmithKline Plc (Hepsera, Zeffix), and Novartis International AG (Sebivo)......68
Table 67: Market Shares of Leading Hepatitis B Drug Manufacturers by Value Sales in Korea (2014) - Percentage Breakdown for Bemis Company, Inc. (BMS), Bukwang Pharmaceutical Co., Ltd (Levovir), GlaxoSmithKline Plc (Hopsera, Zeffix), Novartis International AG (Sebivo), and Others......69
Infectious Disease Drugs......70
Table 68: Market Shares of Leading Infectious Disease Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol- Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......70
Table 69: SciClone Pharmaceuticals, Inc.’s Sales by Geographic Region Worldwide (2013-2014) in Percentage for China and Rest of the World......71
Table 70: SciClone Pharmaceuticals, Inc.’s Sales by Geographic Region Worldwide (2013) in Percentage for China and Rest of the World......72